Intestine May Be a Major Site of Action for the ApoA-I Mimetic Peptide 4F Whether Administered Subcutaneously or Orally

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2011 Mar 30

PMID 21444758

Citations 46

Authors

Mohamad Navab

Srinivasa T Reddy

G M Anantharamaiah

Satoshi Imaizumi

Greg Hough

Susan Hama

Alan M Fogelman

Affiliations

Soon will be listed here.

Abstract

To determine if the dose of peptide administered or the plasma level was more important, doses of 0.15, 0.45, 4.5, or 45 mg/kg/day of the peptide D-4F were administered orally or subcutaneously (SQ) to apoliptotein (apo)E null mice. Plasma levels of peptide were ∼1,000-fold higher when administered SQ compared with orally. Regardless of the route of administration, doses of 4.5 and 45 mg/kg significantly reduced plasma serum amyloid A (SAA) levels and the HDL inflammatory index (P < 0.0001); doses of 0.15 or 0.45 mg/kg did not. A dose of 45 mg/kg/day administered to apoE null mice on a Western diet reduced aortic atherosclerosis by ∼50% (P < 0.0009) whether administered orally or SQ and also significantly reduced plasma levels of SAA (P < 0.002) and lysophosphatidic acid (P < 0.0009). Remarkably, for each dose administered, the concentration and amount of peptide in the feces was similar regardless of whether the peptide was administered orally or SQ. We conclude: i) the dose of 4F administered and not the plasma level achieved determines efficacy; ii) the intestine may be a major site of action for the peptide regardless of the route of administration.

Citing Articles

Peptides as Therapeutic Agents for Atherosclerosis.

White C, Palgunachari M, Wolkowicz P, Anantharamaiah G Methods Mol Biol. 2022; 2419:89-110.

PMID: 35237960 DOI: 10.1007/978-1-0716-1924-7_6.

Oxidized phospholipids cause changes in jejunum mucus that induce dysbiosis and systemic inflammation.

Mukherjee P, Chattopadhyay A, Grijalva V, Dorreh N, Lagishetty V, Jacobs J J Lipid Res. 2021; 63(1):100153.

PMID: 34808192 PMC: 8953663. DOI: 10.1016/j.jlr.2021.100153.

Apolipoprotein mimetics in cancer.

Delk S, Chattopadhyay A, Escola-Gil J, Fogelman A, Reddy S Semin Cancer Biol. 2020; 73:158-168.

PMID: 33188891 PMC: 8110614. DOI: 10.1016/j.semcancer.2020.11.002.

A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE mice.

Gou S, Wang L, Zhong C, Chen X, Ouyang X, Li B Br J Pharmacol. 2020; 177(20):4627-4644.

PMID: 32726461 PMC: 7520440. DOI: 10.1111/bph.15213.

Apolipoprotein-AI mimetic peptides D-4F and L-5F decrease hepatic inflammation and increase insulin sensitivity in C57BL/6 mice.

McGrath K, Li X, Twigg S, Heather A PLoS One. 2020; 15(1):e0226931.

PMID: 31914125 PMC: 6948736. DOI: 10.1371/journal.pone.0226931.

References

Navab M, Anantharamaiah G, Reddy S, Hama S, Hough G, Grijalva V . Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004; 109(25):3215-20. DOI: 10.1161/01.CIR.0000134275.90823.87. View

Garber D, Venkatachalapathi Y, Gupta K, Ibdah J, Phillips M, HAZELRIG J . Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties. Arterioscler Thromb. 1992; 12(8):886-94. DOI: 10.1161/01.atv.12.8.886. View

Navab M, Anantharamaiah G, Reddy S, Hama S, Hough G, Grijalva V . Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005; 25(7):1325-31. DOI: 10.1161/01.ATV.0000165694.39518.95. View

Lam H, Oh D, Cava F, Takacs C, Clardy J, de Pedro M . D-amino acids govern stationary phase cell wall remodeling in bacteria. Science. 2009; 325(5947):1552-5. PMC: 2759711. DOI: 10.1126/science.1178123. View

Navab M, Anantharamaiah G, Hama S, Garber D, Chaddha M, Hough G . Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002; 105(3):290-2. DOI: 10.1161/hc0302.103711. View

Wool G, Cabana V, Lukens J, Shaw P, Binder C, Witztum J . 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J. 2010; 25(1):290-300. PMC: 3005429. DOI: 10.1096/fj.10-165670. View

Navab M, Ruchala P, Waring A, Lehrer R, Hama S, Hough G . A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids. J Lipid Res. 2009; 50(8):1538-47. PMC: 2724044. DOI: 10.1194/jlr.M800539-JLR200. View

Morgantini C, Imaizumi S, Grijalva V, Navab M, Fogelman A, Reddy S . Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes. 2010; 59(12):3223-8. PMC: 2992786. DOI: 10.2337/db10-0844. View

DSouza W, Stonik J, Murphy A, Demosky S, Sethi A, Moore X . Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. Circ Res. 2010; 107(2):217-27. PMC: 2943235. DOI: 10.1161/CIRCRESAHA.110.216507. View

10.

Korza H, Bochtler M . Pseudomonas aeruginosa LD-carboxypeptidase, a serine peptidase with a Ser-His-Glu triad and a nucleophilic elbow. J Biol Chem. 2005; 280(49):40802-12. DOI: 10.1074/jbc.M506328200. View

11.

Bloedon L, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot B . Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res. 2008; 49(6):1344-52. PMC: 2386905. DOI: 10.1194/jlr.P800003-JLR200. View

12.

Su F, Kozak K, Imaizumi S, Gao F, Amneus M, Grijalva V . Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer. Proc Natl Acad Sci U S A. 2010; 107(46):19997-20002. PMC: 2993420. DOI: 10.1073/pnas.1009010107. View

13.

Van Lenten B, Wagner A, Navab M, Anantharamaiah G, Hama S, Reddy S . Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J Lipid Res. 2007; 48(11):2344-53. DOI: 10.1194/jlr.M700138-JLR200. View

14.

PAPPENHEIMER J, Karnovsky M, Maggio J . Absorption and excretion of undegradable peptides: role of lipid solubility and net charge. J Pharmacol Exp Ther. 1997; 280(1):292-300. View

15.

Lewis K, Kirk E, McDonald T, Wang S, Wight T, OBrien K . Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation. 2004; 110(5):540-5. DOI: 10.1161/01.CIR.0000136819.93989.E1. View

16.

Bielicki J, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A . A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J Lipid Res. 2010; 51(6):1496-503. PMC: 3035513. DOI: 10.1194/jlr.M003665. View

17.

Navab M, Anantharamaiah G, Hama S, Hough G, Reddy S, Frank J . D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2005; 25(7):1426-32. DOI: 10.1161/01.ATV.0000167412.98221.1a. View

18.

Watson C, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I . Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res. 2010; 52(2):361-73. PMC: 3023557. DOI: 10.1194/jlr.M011098. View

19.

Kolodkin-Gal I, Romero D, Cao S, Clardy J, Kolter R, Losick R . D-amino acids trigger biofilm disassembly. Science. 2010; 328(5978):627-9. PMC: 2921573. DOI: 10.1126/science.1188628. View

20.

Van Lenten B, Wagner A, Jung C, Ruchala P, Waring A, Lehrer R . Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res. 2008; 49(11):2302-11. PMC: 2563211. DOI: 10.1194/jlr.M800075-JLR200. View